oh come on. You and everyone else in here knows that the next year will determine the future of this company. If the phase I/II trials continue to show the same favorable results, pharma will be all over them for a JV or buyout. They would not wait for the phase III/IV trials. They have enough cash with the present A/S now to sustain them for about 2 years. I don't believe they will need to do any further dilution. If the next set of patients don't continue to show the same results then they are in trouble. I believe in the science of this and do think it will continue to show favorable results especially when they start treating patients with less severe disease. 2012 is going to be the make or break year for this company and I think it is going to make it and thrive and we will all see significant profits. Only time will tell but this is the year.
News 
Market Data 
Discover 
